MAPK Signaling
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
- A3189 AS 602801Summary: Jun Kinase Inhibitor
- A3263 BRAF inhibitorSummary: Potent B-raf inhibitor
- A3264 B-Raf inhibitorSummary: A B-Raf inhibitor
- A3287 CC-401 hydrochlorideSummary: JNK inhibitor
- A3288 CC-930Target: JNKSummary: JNK inhibitor,potent and selective
- A3297 CEP-32496 hydrochlorideSummary: B-Raf/C-Raf inhibitor,highly potent
- A3321 Cobimetinib3 CitationSummary: Selective MEK inhibitor
- A3322 Cobimetinib (racemate)Summary: Selective MEK inhibitor
- A3323 Cobimetinib (R-enantiomer)Summary: Selective MEK inhibitor
- A3347 Dabrafenib Mesylate (GSK-2118436)Target: RafSummary: Inhibitor of BRAF(V600) mutants